1. Introduction {#s0005}
===============

In 1889, Senn inadvertently found that bone rudiments initiate bone formation ([@bb0280]). However, it appears that, Senn had been beaten by about 300 years as the Dutch surgeon, Job van Meekeren recorded the use of dog bone to repair a human cranial defect in 1668 ([@bb0245]). More recently, the work of Urist in 1965 is credited for the discovery that a specific component of bone, which he called BMP or bone morphogenetic protein, induced ectopic bone formation ([@bb0065]; [@bb0430]). His work implanting decalcified bone in muscle pouches led him to prove the osteoinductive properties of BMPs, and hence the derivation of the name. Throughout the 1970\'s Dr. Urist\'s laboratory demonstrated the role of BMPs in bone formation. In the 1980 and early 1990\'s, BMPs were sequenced and cloned which paved the way for their use in clinical applications ([@bb0470]). It is now known that not all BMP ligands induce ectopic bone formation, and various highly homologous BMPs have varying effects on osteogenesis. Some BMPs, such as BMP 3, inhibit bone formation ([@bb0200]), while others, termed osteogenic BMPs (BMPs 2, 4, 5, 6, 7, and 9), are able to induce ectopic bone ([@bb0230]).

1.1. Clinical use and complications of BMPs {#s0010}
-------------------------------------------

In 1988 the first sequences of human BMP ligands were published, and the sequences of other BMP ligands followed soon after. This lead to the clinical use of recombinant BMPs to be approved for acute bone fractures, non-unions and spinal fusions ([@bb0035]; [@bb0055]; [@bb0095]; [@bb0115]; [@bb0190]). Both BMP2 and BMP7 may cause early osteolysis resulting in implant dislodgment in patients following spinal fusion surgery ([@bb0270]; [@bb0375]). These effects may be due to the stimulation of BMP2 on osteoclast differentiation and activity in addition to their osteogenic effects through osteoblasts. To date, most of the research has focused on the effect of BMPs on osteoblasts and bone deposition rather than osteoclasts. In this review, we focus on some of the *in-vitro* and *in-vivo* results available from our lab and others on the regulation of osteoclasts by BMPs.

1.2. Osteoclast biology {#s0015}
-----------------------

The bone is comprised of multiple cell types, including osteoblasts, mesenchymal-derived cells responsible for synthesizing bone and bone degrading osteoclasts, which arise from hematopoietic derived stem cells ([@bb0415]). Bone homeostasis and normal skeletal function result from the proper balance of osteoblasts and osteoclasts. To maintain this balance in the adult skeleton, osteoblasts and/or osteocytes, terminally differentiated osteoblasts, produce two cytokines required to promote osteoclast differentiation, macrophage colony stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL) ([@bb0480]).

Osteoclasts are derived from the monocyte/macrophage lineage. The transcription factor PU.1 which induces expression of c-FMS, the receptor for the cytokine M-CSF, is necessary for commitment to the monocyte/macrophage lineage ([@bb0425]). RANKL stimulation induces expression of the master regulator of osteoclast differentiation, NFATc1, through both c-Fos and NF-κB pathways ([@bb0125]; [@bb0140]; [@bb0395]). M-CSF stimulation has been shown to promote osteoclast precursor proliferation while RANKL stimulates osteoclast precursors to exit the cell cycle and terminally differentiate ([@bb0335]).

As part of terminal differentiation, osteoclast precursors undergo fusion to become multinuclear cells ([Fig. 1](#f0005){ref-type="fig"}). In recent years, proteins necessary for osteoclast fusion have been identified in mouse models. One such protein is DC-STAMP or the "master fusigen" and the related protein OC-STAMP ([@bb0255]; [@bb0485]). Recent work by Verma et al. suggests that one role of DC-STAMP in the fusion process is the exposure of phosphatidylserines on the surface of osteoclasts, and the exposure of these phosphatidylserines regulates the activity of several proteins including annexins, S100A4 and syncytin1 ([@bb0445]). In osteoclasts null for ATP6v0d2, another protein that has been demonstrated to be necessary for osteoclast fusion, there is decreased expression of ADAM 8 and 12 ([@bb0215]). ADAMs cleave extracellular regions of transmembrane proteins and are involved in cell-cell and cell-matrix adhesion providing a possible mechanism by which ATP6v0d2 regulates osteoclast fusion ([@bb0215]).Fig. 1Osteoclast differentiation. Drawing depicts osteoclast differentiation and proteins involved in commitment, fusion and activity. Names of proteins under each heading are involved in the process described by the heading but does not indicate time of expression during osteoclast differentiation. Proteins involved in BMP signaling are highlighted in pink and based on data presented in [@bb0150] and [@bb0325]. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 1

Small GTPases such as Rho, Rac and Cdc42 have been shown to be involved in osteoclast differentiation, resorption and survival (as reviewed in [@bb0455]). Guanine nucleotide exchange factors (GEFs) such as Vav3 which link small GTPases with integrins have also been shown to be essential for osteoclast activity ([@bb0085]). For bone resorption to begin, multinuclear osteoclasts must attach to the bone surface. This attachment which occurs through activation of integrins and c-Src, a RANKL activated kinase, results in the cytoskeleton being rearranged to allow for fusion and resorption ([@bb0040]; [@bb0415]; [@bb0420]). Osteoclasts express the integrin αvβ3 which recognizes the arginine-glycine-aspartic acid (RGD) peptide expressed in bone matrix proteins ([@bb0420]). Besides allowing for the attachment of osteoclasts to bone matrix proteins, αvβ3 along with actin binding proteins such as vinculin and talin surround an F-actin core to form numerous podosomes, a structure essential for osteoclast resorption ([@bb0100]; [@bb0500]). Podosomes condense into a thick ring of actin which allows for the attachment to the bone surface to form a sealing zone where acidified cytoplasmic vesicles are transported ([@bb0155]; [@bb0310]; [@bb0345]; [@bb0340]; [@bb0385]). Besides attachment, the sealing zone allows for the "sealing off" of the resorptive pit into which osteoclasts secrete proteases such as cathepsin K as well as H^+^ and Cl^−^ ([@bb0355]). Optimal bone resorption is a cycle consisting of cell migration to a resorption site, resorption of the underlying bone matrix, detachment and migration to next resorption site. Integrins are necessary for all the steps in this process ([@bb0110]). During bone resorption by the osteoclast, growth factors embedded in the bone matrix are released and either recruit osteoblasts to the areas of resorption or help stimulate osteoblast activity ([@bb0070]).

1.3. BMP structure and function {#s0020}
-------------------------------

BMPs are a large family of growth factors that have been demonstrated to regulate development and/or maintenance of adipose, neurological, ophthalmic, cardiovascular, pulmonary, gastrointestinal, urinary and musculoskeletal systems ([@bb0005]; [@bb0060]; [@bb0450]). The BMP family resides within the larger TGF-β super-family, which is defined by its ability to bind to serine or threonine in cell surface receptors. In cell types other than osteoclasts, BMPs have been shown to initiate chemotaxis, cell growth, differentiation, and apoptosis; however, in osteoclasts BMPs have been shown to enhance differentiation, activity, and inhibit apoptosis ([@bb0050]; [@bb0090]; [@bb0150]; [@bb0325]; [@bb0450]). BMPs usually function by short-range diffusion, although they can create a gradient by binding to extracellular BMP binding proteins such as noggin, chordin, gremlin, and twisted gastrulation. The subfamily of BMPs is large with 30 known ligands, and they comprise one third of the known TGF-β superfamily ligands ([@bb0005]; [@bb0045]; [@bb0450]).

BMP ligands are produced as precursor proteins that are dimerized in the cytoplasm before being cleaved and secreted in their mature form. They function by binding to BMP receptors, which induces formation of a hetero-tetrameric receptor unit consisting of two type 1 receptors and two type 2 receptors ([@bb0260]; [@bb0450]). Both type 1 and type 2 receptors are single pass transmembrane proteins with an extracellular domain and a cytoplasmic domain with serine/threonine kinase function ([@bb0260]). There are three type 1 receptors capable of binding to BMP ligands (BMPR-1A, BMPR-1B, ActR-1A); and three type 2 receptors also with the ability to bind to BMP ligands (BMPR-2, ActR-2A, ActR-2B) ([@bb0260]). BMP ligand-receptor complex affinity vary by both ligand and receptor type ([@bb0275]). BMPs can also bind to a preformed receptor complex; in this case constitutively active BMPR-2 is already linked to BMPR-1 for BMP binding. BMPR-2 phosphorylates BMPR-1 which in turn leads to activation of SMAD 1/5/9 pathway. SMAD 1/5/9 is known as the canonical BMP signaling pathway (reviewed in [@bb0260]). A second mechanism for BMP ligands to activate BMP signaling is when BMP receptors are not dimerized but binding of BMP ligand to BMPR-1A recruits BMPR-2 into a complex, which is internalized *via* caveolae ([@bb0260]). This signaling complex has been shown to initiate non-SMAD pathways or non-canonical signaling pathways such as MAPK signaling ([@bb0260]).

2. BMP ligands expression in osteoclast {#s0025}
=======================================

2.1. Indirect regulation of osteoclasts by BMP {#s0030}
----------------------------------------------

As will be described in the following sections, multiple groups have shown that BMPs can directly regulate osteoclast differentiation. However, earlier studies demonstrated that BMPs regulate osteoclast differentiation indirectly through actions on chondrocytes, osteoblasts and osteocytes. As early as 1995, cultures of rat bone marrow cells treated with OP-1 were demonstrated to enhance the ability of vitamin D~3~ to induce formation of TRAP positive osteoclasts *in vitro* ([@bb0130]). Both murine and chicken chondrocytes have been shown to express *RankL* mRNA and protein which was significantly enhanced by BMP2/SMAD1 activation ([@bb0435]). It has been suggested that RANKL protein expression from chondrocytes can regulate osteoclast differentiation at growth plates to remove calcified matrix through BMP induction ([@bb0435]). Kanatani et al. were the first to demonstrate that BMP2 could stimulate mature osteoclasts in the presence but not absence of stromal cells ([@bb0170]). Other studies have shown that BMP2 stimulates bone resorption by osteoclasts through modulation of *Rankl* mRNA expression by stromal cells ([@bb0120]; [@bb0390]). Other groups have demonstrated that BMP2 can modulate the expression of *Opg* mRNA by osteoblasts ([@bb0135]). BMP2 in combination with IL-1α was shown to upregulate expression of *Rankl* mRNA by osteoblasts and indirectly enhance osteoclast differentiation hinting that BMP2 may enhance bone resorption during conditions resulting in inflammation ([@bb0195]). Additionally, PGE~2~ treatment of osteoblast/osteoclast cultures increase the *RankL* to *Opg* mRNA ratio and thereby indirectly regulates osteoclast differentiation ([@bb0030]). Even BMP inhibitors such as Noggin have been shown to affect osteoclast differentiation through Noggin\'s effect on stromal/osteoblast differentiation ([@bb0010]). Noggin\'s direct effect on osteoclast differentiation will be discussed in a later section of this review labelled "BMP inhibitors". Analysis of a mouse model with deletion of *Bmpr1a* in osteoblasts demonstrates an increase in bone mass due to disruption in the ratio of RANKL to OPG protein resulting in a decrease in osteoclast differentiation and activity ([@bb0160]). Until more recently, the critical role of osteocytes in regulating skeletal development were not well understood. In a mouse model using *Dmp1-Cre* to disrupt *Bmpr1a* in osteocytes, the authors determined that the expression of *Opg* bone mRNA was increased and *RankL* bone mRNA was decreased, leading to a sharp reduction in osteoclast differentiation and activity ([@bb0165]). These results are similar to the observations noted in mice null for *Bmpr1a* in osteoblasts. These data collectively suggest that BMPs can act on other skeletal cells and indirectly regulate osteoclast differentiation and activity.

2.2. Direct regulation of osteoclasts by BMP {#s0035}
--------------------------------------------

In recent years, it has become more evident that BMPs also have direct effects on osteoclast differentiation. Further elucidation on the mechanisms by which different ligands induce responses is necessary to fully understanding the role of BMPs in the skeleton. With the increasing use of BMPs in the clinic for osteogenic purposes, clinicians should possess a solid understanding of the effects of BMPs on osteoclasts which may negate the desired effect. By immunohistochemical staining, osteoclasts were demonstrated to express BMP ligands 2, 4, 6 and 7 and later confirmed by others through RT-qPCR and western blot ([@bb0105]; [@bb0150]; [@bb0175]; [@bb0240]; [@bb0285]). In the following sections, we will discuss what is known about individual BMP ligands, and their effects on osteoclast differentiation and activity.

2.3. BMP1 {#s0040}
---------

Originally BMP1 was incorrectly categorized as a member of TGF-β superfamily but in reality, it is a zinc dependent metalloproteinase shown to cleave the C-terminus of procollagen type I, II and III ([@bb0180]; [@bb0350]). BMP1 is a protease important in the activation of TGF-β and BMP2/4 and is involved in processes such as morphogenesis, tissue repair and tumor progression (reviewed in [@bb0440]). Anderson et al. demonstrated that rat and human osteoclasts express BMP1 protein in their cytoplasm; however, the function of BMP1 in osteoclasts is still unknown ([@bb0015]).

2.4. BMP2 {#s0045}
---------

Multiple groups of researchers have demonstrated that osteoclasts express *Bmp2* mRNA in both early lineage cells (bone marrow macrophages) and mature osteoclasts ([@bb0145]; [@bb0150]). In early hematopoietic stem cells, BMP2 can increase or decrease cell proliferation, depending on concentration, but BMP stimulation did not affect cell lineage commitment ([@bb0025]). This differential response to BMP2 may be a method of regulating maintenance or cell expansion of early lineage cells. In lineage committed mononuclear osteoclast precursors, BMP2 acts to enhance survival and proliferation, and its phenotypic effect can be potentiated by IL-1α, prostaglandin, vitamin D3, and PTH ([@bb0010]; [@bb0145]; [@bb0195]).

We are currently investigating the phenotype of mice null for *Bmp2* expression in osteoclasts. In our analysis of the *in vitro* cultures of osteoclasts from *Bmp2*^*fl/fl*^*;LysM-Cre* mice, the cells are smaller but more numerous than in the wild type littermates (Mansky/Gopalakrishnan, unpublished results). These data support our studies and the studies of others that BMP2 enhances osteoclast size but is not necessary for osteoclast differentiation.

2.5. BMP3 {#s0050}
---------

BMP3, also known as osteogenin, or a "non-canonical" BMP, is the most abundant BMP in the bone matrix, embedded by osteoblasts and osteocytes (\>65% of BMP stored in bone ([@bb0075])). It acts as a negative regulator of bone density by inhibiting osteoblast differentiation ([@bb0075]). However, BMP3 expression has not yet been reported in osteoclasts and cartilage and is thought to be expressed primarily by mature osteoblasts ([@bb0200]).

2.6. BMP4 {#s0055}
---------

BMP4 is closely related to BMP2, and both share common osteogenic functions. Global knockouts for BMP4 are embryonically lethal before the onset of skeletogenesis ([@bb0465]). In mice with a conditional deletion of *Bmp2* and *Bmp4* using *Prx1-Cre*, there is a delay in endochondral process partially due to a delay in osteoclast recruitment to the mineralized cartilage ([@bb0020]). Both BMP2 and 4 protein is highly expressed by osteoclasts at fracture sites ([@bb0380]). Overexpression of BMP4 in bone (*Col1a1-Bmp4*) leads to osteopenia due to increased osteoclast number ([@bb0285]). These mice however, die shortly after birth making it difficult to study skeletal development ([@bb0285]). BMP4 was shown to upregulate OPG in ST2 cell line suggesting that BMP4 could indirectly regulate osteoclast differentiation through modulation of the RANKL/OPG ratio ([@bb0410]).

2.7. BMP5 {#s0060}
---------

Due to their interesting phenotype, BMP5 knockout mice have been studied for almost 100 years, although at the time, and for about 75 years after, researchers did not know that the mice were BMP5 deficient ([@bb0185]). Later BMP5 studies were able to clarify its role in bone homeostasis. BMP5 is able to stimulate osteoclast formation in a biphasic mode, although stimulation requires higher doses than BMP2 ([@bb0475]). Combinations of BMP2, 5 and 6 can stimulate osteoblastogenesis but had no additive effect on osteoclast differentiation ([@bb0475]). Lastly, giant cell tumors have been shown to express BMP5 as well as other BMP ligands ([@bb0205]).

2.8. BMP6 {#s0065}
---------

Although most closely related to BMP5, BMP6 acts in an opposing manner to BMP5 in osteoclasts. In co-cultures with osteoclasts and osteoblasts, BMP6 inhibits osteoclastogenesis ([@bb0370]). This effect was shown to be indirect, working through osteoblasts. BMP6 mRNA and protein expression increases during osteoclast differentiation ([@bb0305]). BMP6 expressed by osteoclasts may also regulate bone formation. Conditioned media from mature osteoclasts stimulated mesenchymal cell nodule formation and was attenuated by a BMP6 neutralizing antibody ([@bb0305]).

2.9. BMP7 {#s0070}
---------

BMP7, also called OP1, was discovered in 1990 ([@bb0295]). In human osteoclast cultures, BMP7 inhibited CD14+ monocytes differentiation into osteoclasts ([@bb0235]). *c-Fos* and *Nfatc1* protein expression were upregulated but were not stable in the presence of BMP7, and *MafB*, an inhibitor of osteoclast differentiation, was not downregulated in the presence of BMP7 ([@bb0235]).

2.10. BMP8 {#s0075}
----------

BMP8 is expressed in developing skeletal tissues but does not seem to play an important role in osteoclastogenesis ([@bb0080]; [@bb0300]). There is no research to date to suggest that BMP8 regulates osteoclast differentiation or activity.

2.11. BMP9 {#s0080}
----------

BMP9 increases osteoclast resorption and survival by activation of the SMAD pathway ([@bb0090]). Recently BMP9 has been shown to enhance osteoclast differentiation by upregulating ALK1 receptor and inhibiting activation of the ERK1/2 signaling pathway ([@bb0220]).

3. BMP inhibitors {#s0085}
=================

BMP signaling is tightly regulated by multiple extracellular binding proteins, which modulate the diffusion from a source and control BMP signaling ([@bb0330]). Multiple extracellular BMP regulators exist and can both regulate the function of BMPs but can also regulate each other ([@bb0330]). Mice with a global knockout of the BMP inhibitor *Twisted gastrulation* (*Twsg1*) demonstrated increased numbers, size and activity of osteoclasts but no detectable change in osteoblast activity ([@bb0325]). Osteoclasts from the *Twsg1* knockout mice also have increased phosphorylated SMAD1/5/8 expression ([@bb0325]). Additionally, osteoclast differentiation was inhibited by overexpression of *Twsg1* ([@bb0315]). Mice overexpressing Noggin, another extracellular BMP modulator, showed increased bone volume due to decreased bone formation and resorption ([@bb0285]). Co-culture experiments with osteoblasts from *noggin* overexpressing mice demonstrated that Noggin inhibits osteoclast formation by attenuating BMP activities in osteoclasts as osteoclast differentiation could be rescued by addition of BMP2 ([@bb0010]; [@bb0285]). Jensen et al. demonstrated that addition of recombinant Noggin to osteoclast cultures before day 3 inhibited osteoclast fusion and differentiation while Noggin addition after day 3 resulted in no significant change in osteoclast differentiation ([@bb0150]). Lastly, a group of researchers demonstrated that osteoclasts express *sclerostin* which can inhibit BMP6 and BMP7 but not BMP2 or BMP4 ([@bb0210]). They demonstrated that *sclerostin* is secreted only by bone resorbing osteoclasts, and therefore, may be a mechanism by which bone apposition is inhibited in the vicinity of bone resorption ([@bb0210]). However, expression of *sclerostin* by osteoclasts has not been reported by others and remains controversial.

4. BMP receptors {#s0090}
================

Multiple studies have demonstrated that osteoclasts express BMP receptors *Bmpr-1a*, *Bmpr-1b* and *Bmpr-2* mRNA and protein ([@bb0050]; [@bb0105]; [@bb0150]; [@bb0175]; [@bb0290]; [@bb0360]; [@bb0365]). The mechanism(s) in osteoclasts that regulate expression of BMP receptors is unknown. However, in unpublished studies from our lab, we did not measure any change in expression of BMP receptors by RT-qPCR in TWSG1 null osteoclasts, suggesting that BMP signaling itself may not regulate expression of BMP receptors in osteoclasts.

4.1. BMPR-2 {#s0095}
-----------

Our group deleted *Bmpr-2* from all cells in the myeloid lineage including osteoclasts, and the conditional knockout mice were osteopetrotic due to decreased osteoclast differentiation ([@bb0050]). *Bmpr-2* conditional knockout mice had changes in the noncanonical signaling pathway (MAPK) and no changes in the canonical (SMAD1/5/8) signaling in the knockout mice compared to wild type ([@bb0050]). Data from other studies suggest that in the *Bmpr-2* conditional mouse model the amino-terminus of the BMPR-2 receptor may still be expressed and able to continue to activate the SMAD signaling pathway ([@bb0490]). Due to the defective osteoclast differentiation, these mice are osteopetrotic, displaying increased bone volume and increased trabeculae ([@bb0050]). Interestingly, in this animal model, it was not the osteoclast number on the bone surface that was altered, but the activity of these osteoclasts *in-vivo* ([@bb0050]).

4.2. BMPR-1A {#s0100}
------------

Mice expressing a conditional deletion of *Bmpr1a* in mature osteoclasts (*Bmpr1a*^*fl/fl*^*;Ctsk-Cre*) demonstrated increased bone resorption, suggesting that activation of BMPR-1A in the late stages of osteoclast differentiation negatively regulates osteoclast activity ([@bb0290]). Additionally, mice with a deletion of *Bmpr-1a* in osteoclasts measured increase bone formation, suggesting that BMPR-1A signaling in osteoclasts regulates osteoclast and osteoblast coupling ([@bb0290]). Recently, *Bmpr-1a* was conditionally deleted from osteoclasts with *LysM-Cre* which would decrease BMPR-1A protein expression in all myeloid cells. The osteoclasts from these mice were decreased in their ability to form multinuclear TRAP positive cells with decreased expression of SMAD1/5/8 protein; however, even though mRNA for *Mitf* and *Pu.1* were increased, *Nfatc1* and other late osteoclast genes were decreased ([@bb0225]).

4.3. BMPR-1B {#s0105}
------------

Global knockouts of *Bmpr-1b* have an osteopenic phenotype ([@bb0360]). *In-vivo* analysis of bone activity markers indicates that neither bone formation nor resorption is changed in the global *Bmpr-1b* mice ([@bb0360]). *In-vitro* cultures of osteoclasts from BMPR-1B null mice revealed increased proliferation of osteoclast precursors, more osteoclast differentiation, reduced apoptosis but surprisingly also reduced resorption ([@bb0360]).

5. BMP signaling {#s0110}
================

As stated earlier, BMPs can signal through both a noncanonical signaling pathway, or SMAD-independent signaling pathway, and canonical signaling pathway, which is the SMAD-dependent signaling pathway ([Fig. 2](#f0010){ref-type="fig"}).Fig. 2Intersection of BMP and RANKL signaling pathways. Cartoon depicts downstream proteins activated by BMP and/or RANKL signaling pathways. Both pathways are able to activate TAK1 kinase which allows for activation of MAP kinase, SMAD1/5 and NF-kB ([@bb0320]).Fig. 2

5.1. Noncanonical signaling {#s0115}
---------------------------

While not known in osteoclasts, BMP signaling has been shown to activate PI3K/Akt, P/kC and Rho-GTPases (reviewed in [@bb0495]). All of these kinases have been shown to regulate osteoclast differentiation and activation (as reviewed in [@bb0250]). It has been shown that mitogen activated protein kinases or MAPKs are activated by BMP signaling in osteoclasts. Mice null for TAK1 expression, a MAPKKK, in mature osteoclasts led to a decrease in SMAD1/5/9 signaling in osteoclasts ([@bb0320]). This data suggests that BMPs can activate both noncanonical and canonical signaling *via* TAK1 in osteoclasts. BMP2 stimulation has been shown to activate MAPKs, ERK1/2, JNK and p38 in osteoclasts ([@bb0050]). Itoh et al. demonstrated that BMP2 cannot activate NF-κB in osteoclasts but rather it inhibits NF-κB activation by RANKL ([@bb0145]). In osteoclasts, BMP9 stimulation has been shown to activate both SMAD1/5/8 and ERK1/2 ([@bb0090]). BMP9 was shown to activate ERK1/2 through BMPR-2, as loss of BMPR-2 expression led to loss of ERK1/2 but not SMAD activation ([@bb0090]).

5.2. Canonical signaling {#s0120}
------------------------

The R-Smads are phosphorylated and associate with a common Smad4 ([@bb0450]). The R-Smad/Smad4 complex translocate to the nucleus to regulate gene expression ([@bb0450]). Multiple research groups have demonstrated that osteoclasts express phosphorylated R-SMADs as well as SMAD4 ([@bb0150]; [@bb0265]; [@bb0400]).

### 5.2.1. SMAD1/5/9 {#s0125}

In our initial study of the necessity of *Smad1/5/9* expression during osteoclast differentiation, we first established by RT-qPCR that osteoclasts express only detectable levels of *Smad1* and *Smad5* but not *Smad9* ([@bb0400]). Osteoclast precursors isolated from the femurs of *Smad1/5*^*fl/fl*^ mice infected with an adenovirus expressing CRE were inhibited in their ability to differentiate and resorb a calcium phosphate substrate ([@bb0400]). We detected no change in *c-Fos* and *Nfatc1* mRNA expression but did measure a decrease in *Dc-stamp* and *Ctsk* mRNA expression ([@bb0400]). To further characterize the role of SMAD1/5 during osteoclast differentiation, we created *Smad1/5* conditional knockouts in osteoclasts ([@bb0405]). Loss of *Smad1/5* expression in the myeloid lineage had no significant effect on the skeleton; however, loss of Smad1/5 expression in macrophage/osteoclasts and mature osteoclasts enhanced osteoclast differentiation ([@bb0405]). Surprisingly, we measured increased cortical thickness and an increase in osteoblast activity by P1NP ELISA ([@bb0405]). Lastly, conditioned media from SMAD1/5 null osteoclasts increased mineralization of MC3T3 cells compared to wild type conditioned media, and expression of known osteoclast/osteoblast coupling factors were increased in SMAD1/5 null osteoclasts ([@bb0405]).

### 5.2.2. SMAD4 {#s0130}

*In-vitro* cultures of *Smad4*^*fl/fl*^ infected with CRE expressing adenovirus demonstrated that loss of SMAD4 expression during the early stages of osteoclast differentiation results in the loss of osteoclast differentiation ([@bb0400]). We measured less expression of *Nfatc1*, *Dc-stamp* and *Ctsk* by RT-qPCR as well as decrease in pSMAD2/3 expression by western blot ([@bb0400]). However, conditional deletion of *Smad4* in mature osteoclasts (*Smad4f*^*l/fl*^*;Ctsk-Cre*) results in osteopenia due to increased osteoclast differentiation ([@bb0265]). The changes in osteoclast differentiation were not due to changes in BMP signaling but due to changes in the sensitivity to TGF-β signaling ([@bb0265]). Morita et al. demonstrated that TGF-β1 signaling blocks expression of *Prdm1* mRNA, a repressor of osteoclast differentiation ([@bb0265]). Loss of *Prdm1* expression upregulates expression of *Bcl-6* and *Irf8* RNA, both of which are repressors of osteoclast differentiation ([@bb0265]). Summary of BMP activities during osteoclast differentiation is shown in [Fig. 3](#f0015){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}.Fig. 3Role of BMPs in regulating osteoclast differentiation. "Up" arrows indicate that BMP2 positively regulates osteoclast proliferation and RANKL expression. Loss of BMPR-2 or BMPR-1 in myeloid cells leads to loss of osteoclast differentiation. TWSG1, Noggin or SMAD4 expression leads to inhibition of osteoclast differentiation. Lastly BMPR-1A and SMAD1/5 have been shown in mature osteoclasts to regulate osteoclast-osteoblast coupling signals.Fig. 3Table 1Table of BMP/osteoclast mouse models.Table 1GenotypeSkeletal phenotypeOsteoclast phenotypeReference*Twsg1*OsteopenicEnhanced osteoclasts\
Increased SMAD1/5 activation([@bb0325])*Bmpr-2;LysM-Cre*OsteopetroticDecreased, smaller osteoclasts, Changes in noncanonical, no change in SMAD1/5 signaling([@bb0050])*Smad1/5;Cfms-Cre*OsteopenicIncreased osteoclast activity and bone formation([@bb0400])*Bmpr-1A;Ctsk-Cre*OsteopetroticIncreased bone formation([@bb0290])*Bmpr-1A;LysM-Cre*OsteopenicDecreased fusion([@bb0225])*Smad4;Ctsk-Cre*OsteopenicIncreased osteoclast differentiation due to changes in TGF-*β* signaling([@bb0265])

6. Coupling of bone formation and resorption by BMPs {#s0135}
====================================================

As stated in the beginning of this review, BMPs indirectly regulate osteoclast differentiation and activity through modulation of RANKL and OPG. With the creation of mice null for components of the BMP signaling pathway in osteoclast lineage cells, it has become clear that BMPs also regulate expression of osteoclast factors that couple bone resorption and bone formation. Mice null for *Bmpr1a* in mature osteoclasts demonstrate changes in bone formation which led to the conclusion that BMP signaling in osteoclasts negatively regulates osteoblast mineralization ([@bb0365]). Additionally, the increase in bone formation in BMPR1A null mice suggests that BMPR1A signaling in osteoclasts regulates osteoclast and osteoblast coupling ([@bb0290]). Osteoclasts are able to recruit osteoblasts to sites of bone remodeling through osteoclast-osteoblast signaling ([@bb0305]; [@bb0365]; [@bb0460]). There have been numerous potential coupling factors discovered as of recent. Expression of CX43/GJA1 was increased in *Bmpr1a*-null osteoclasts and was demonstrated to be a downstream target of BMPR1A signaling in osteoclasts and can mediate osteoclast-osteoblast communication during remodeling ([@bb0365]). As stated above in our SMAD1/5 cKO mice, we measured changes in bone formation, an increase in *Wnt1*, *Gja1* and *Sphk1* mRNA expression and conditioned media from SMAD1/5 null osteoclasts enhanced the ability of MC3T3 cells to mineralize. Future studies will confirm which changes are responsible for the increase in bone formation and what other coupling factors are regulated by BMP ([Fig. 4](#f0020){ref-type="fig"}).Fig. 4BMP signaling regulates osteoclast-osteoblast coupling. Osteoclasts secrete BMPs such as BMP6 or other factors such as Wnts regulated by BMP signaling to activate pre-osteoblasts\' differentiation or bone formation by mature osteoblasts. During bone resorption osteoclasts release BMPs stored in the bone matrix. BMP signaling has also been shown to regulate expression of CX43/GJA1 in osteoclasts which interacts with osteoblast to regulate mineralization ([@bb0365]).Fig. 4

7. Conclusions {#s0140}
==============

BMP plays a critical and complex role in bone development and homeostasis. The ability to culture osteoclasts without supporting cells *in-vitro* has allowed multiple groups to determine the direct effects of individual BMP ligands in regulating osteoclast differentiation. Additionally, the ability to create knockout mice in cells of the osteoclast lineage has and will continue to provide insight into the necessity for BMP ligands and receptors in regulating osteoclast differentiation and activity. These fundamental studies are necessary to understand the function of BMPs in bone, and understand their physiological effects, from signaling process, and cell-cell interactions that BMPs activate when used in the clinical setting.
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